USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
G1 THERAPEUTICS, INC.
Address:
450 WEST DR, CB 7295
CHAPEL HILL, NC
Phone:
N/A
URL:
N/A
EIN:
126364818
DUNS:
828732813
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,003,277.00 3
SBIR Phase II $3,000,000.00 1

Award List:

Organismal Radioprotection Through Pharmacological Quiescence

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$692,326.00
Agency:
HHS
Principal Investigator:
John S. Chant
Abstract:
DESCRIPTION (provided by applicant): Hematologic toxicity is a principal cause of morbidity and mortality after exposure to ionizing radiation (IR). G-Zero Therapeutics, with operations in the Research Triangle Park, North Carolina, has developed a nov el approach to mitigating the hematologic… More

Organismal Radioprotection Through Pharmacological Quiescence

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$3,000,000.00
Agency:
HHS
Principal Investigator:
Jay C. Strum – 919-966-9755
Abstract:
DESCRIPTION (provided by applicant): Syndrome (ARS), including a lethal myelosuppression due to the sensitivity of proliferating hematopoietic stem/progenitor cells (HSPCs) to ionizing radiation (IR). No effective therapy exists to mitigate the hematologictoxicities of TBI. Herein G-Zero… More

Development of CDK4/6 Inhibitors as Novel Renal Protectants

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$159,836.00
Agency:
HHS
Principal Investigator:
Jay C. Strum – 919-966-9755
Abstract:
DESCRIPTION (provided by applicant): Acute kidney injury (AKI) is common, expensive, and highly morbid. There are currently no therapies for AKI, and prevention and treatment represents a 6.3 billion market opportunity annually in the U.S. Moreover, patients are developing AKI more frequently and… More

A new multiphase polymeric material for cushion-bearing orthopedic implants

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$151,115.00
Agency:
HHS
Principal Investigator:
Jay C. Strum – 919-966-9755
Abstract:
DESCRIPTION (provided by applicant): Myelosuppression continues to represent the major dose-limiting toxicity of cancer chemotherapy, resulting in considerable morbidity and mortality along with frequent reductions in chemotherapy dose intensity, which maycompromise disease control and survival.… More